Background/Aims: Alzheimer's disease (AD) is an irreversible neurodegenerative disorder and is the commonest form of dementia. One aim of this study was to determine whether AD individuals have altered plasma folate, vitamin B12 and homocysteine (Hcy) levels compared to controls. The other aim was to investigate correlations between B vitamins and buccal biomarkers to test whether they are influenced by B vitamin status. Methods: Folate, vitamin B12 and Hcy were measured using ARCHITECT® and AxSYM® assays. Genomic stability was measured using the buccal micronucleus cytome assay. Results: The area under the receiver operating characteristic curve for AD basal cells was 0.96 (p < 0.0001), for karyorrhectic cells 0.88 (p < 0.0001) and for basal and karyorrhectic cells 0.91 (p < 0.0001). Hcy was significantly increased (p = 0.0003) compared to controls. Plasma vitamin B12 in controls showed a positive correlation with pyknosis (r = 0.5365, p = 0.004), karyolysis (r = 0.5447, p = 0.004) and condensed chromatin (r = 0.5238, p = 0.006). Plasma vitamin B12 in AD cases showed a positive correlation with micronuclei (r = 0.3552, p = 0.04) and basal cells (r = 0.3448, p = 0.04), whilst plasma Hcy showed a negative correlation with karyorrhectic cells (r = -0.4107, p = 0.01). Conclusions: Hcy was significantly increased in AD cases relative to controls. The lower frequency of basal cells and karyorrhectic cells observed in AD cases may be explained by lower vitamin B12 and higher Hcy levels, respectively.

1.
Spuch C, Ortolano S, Navarro C: New insights in the amyloid-beta interaction with mitochondria. J Aging Res 2012:324968.
2.
Aisen PS, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, et al: A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:246-249.
3.
Shea TB, Lyons-Weiler J, Rogers E: Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheimers Dis 2002;4:261-267.
4.
Shea TB, Rogers E: Homocysteine and dementia. N Engl J Med 2002;346:2007, author reply 2008.
5.
Kruman, II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al: Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002;22:1752-1762.
6.
Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, et al: Homocysteine potentiates β-amyloid neurotoxicity: role of oxidative stress. J Neurochem 2001;78:249-253.
7.
Sai X, Kawamura Y, Kokame K, Yamaguchi H, Shiraishi H, Suzuki R, et al: Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid β-protein. J Biol Chem 2002;277:12915-12920.
8.
Tagliari B, Zamin LL, Salbego CG, Netto CA, Wyse AT: Homocysteine increases neuronal damage in hippocampal slices receiving oxygen and glucose deprivation. Metab Brain Dis 2006;21:273-278.
9.
Ford AH, Flicker L, Hankey GJ, Norman P, van Bockxmeer FM, Almeida OP: Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and cognitive impairment: the Health in Men Study. Mol Psychiatry 2012;17:559-566.
10.
Choi SW, Mason JB: Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 2002;132(8 suppl): 2413S-2418S.
11.
Choi SW, Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129-132.
12.
Blount BC, Ames BN: DNA damage in folate deficiency. Baillieres Clin Haematol 1995;8:461-478.
13.
Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, et al: Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997;94:3290-3295.
14.
Zingg JM, Jones PA: Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869-882.
15.
Calvaresi E, Bryan J: B vitamins, cognition, and aging: a review. J Gerontol B Psychol Sci Soc Sci 2001;56:P327-P339.
16.
Wang X, Thomas P, Xue J, Fenech M: Folate deficiency induces aneuploidy in human lymphocytes in vitro - evidence using cytokinesis-blocked cells and probes specific for chromosomes 17 and 21. Mutat Res 2004;551:167-180.
17.
Beetstra S, Thomas P, Salisbury C, Turner J, Fenech M: Folic acid deficiency increases chromosomal instability, chromosome 21 aneuploidy and sensitivity to radiation-induced micronuclei. Mutat Res 2005;578:317-326.
18.
Thomas P, Fenech M: Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease. Mutagenesis 2007;23:57-65.
19.
Thomas P, Hecker J, Faunt J, Fenech M: Buccal micronucleus cytome biomarkers may be associated with Alzheimer's disease. Mutagenesis 2007;22:371-379.
20.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21.
Thomas P, Holland N, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, et al: Buccal micronucleus cytome assay. Nat Protoc 2009;4:825-837.
22.
Bolognesi C, Knasmueller S, Nersesyan A, Thomas P, Fenech M: The HUMNxl scoring criteria for different cell types and nuclear anomalies in the buccal micronucleus cytome assay - an update and expanded photogallery. Mutat Res 2013;753:100-113.
23.
Fenech M, Aitken C, Rinaldi J: Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis 1998;19:1163-1171.
24.
Fenech MF, Dreosti IE, Rinaldi JR: Folate, vitamin B12, homocysteine status and chromosome damage rate in lymphocytes of older men. Carcinogenesis 1997;18:1329-1336.
25.
Joosten E, Lesaffre E, Riezler R, Ghekiere V, Dereymaeker L, Pelemans W, et al: Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci 1997;52:M76-M79.
26.
Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L: Vitamin B12 and folate in relation to the development of Alzheimer's disease. Neurology 2001;56:1188-1194.
27.
Selhub J, Bagley LC, Miller J, Rosenberg IH: B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71:614S-620S.
28.
Fowler B: Genetic defects of folate and cobalamin metabolism. Eur J Pediatr 1998;157(suppl 2):S60-S66.
29.
Antony AC: The biological chemistry of folate receptors. Blood 1992;79:2807-2820.
30.
Habibzadeh N, Schorah CJ, Seller MJ, Smithells RW, Levene MI: Uptake and utilization of DL-5-[methyl-14C] tetrahydropteroylmonoglutamate by cultured cytotrophoblasts associated with neural tube defects. Proc Soc Exp Biol Med 1993;203:45-54.
31.
Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, et al: Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 2005;26:567-573.
32.
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-767.
33.
Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, et al: Active glycation in neurofibrillary pathology of Alzheimer disease: Nε-(carboxymethyl)lysine and hexitol-lysine. Free Radic Biol Med 2001;31:175-180.
34.
McCaddon A, Regland B, Hudson P, Davies G: Functional vitamin B12 deficiency and Alzheimer disease. Neurology 2002;58:1395-1399.
35.
Pogribna M, Melnyk S, Pogribny I, Chango A, Yi P, James SJ: Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet 2001;69:88-95.
36.
Aguilar B, Rojas JC, Collados MT: Metabolism of homocysteine and its relationship with cardiovascular disease. J Thromb Thrombolysis 2004;18:75-87.
37.
Gabbita SP, Lovell MA, Markesbery WR: Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998;71:2034-2040.
38.
Lovell MA, Gabbita SP, Markesbery WR: Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 1999;72:771-776.
39.
Mecocci P, Polidori MC, Ingegni T, Cherubini A, Chionne F, Cecchetti R, et al: Oxidative damage to DNA in lymphocytes from AD patients. Neurology 1998;51:1014-1017.
40.
Mecocci P, MacGarvey U, Beal MF: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994;36:747-751.
41.
Fenech M: The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57-67.
42.
Miller JW: Assessing the association between vitamin B-12 status and cognitive function in older adults. Am J Clin Nutr 2006;84:1259-1260.
43.
McCracken C, Hudson P, Ellis R, McCaddon A: Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr 2006;84:1406-1411.
44.
Miller JW: Homocysteine and Alzheimer's disease. Nutr Rev 1999;57:126-129.
45.
Miller JW: Homocysteine, Alzheimer's disease, and cognitive function. Nutrition 2000;16:675-677.
46.
Morris MS: Homocysteine and Alzheimer's disease. Lancet Neurol 2003;2:425-428.
47.
Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al: Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005;82:636-643.
48.
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
49.
Ho PI, Ortiz D, Rogers E, Shea TB: Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002;70:694-702.
50.
Piyathilake CJ, Macaluso M, Hine RJ, Vinter DW, Richards EW, Krumdieck CL: Cigarette smoking, intracellular vitamin deficiency, and occurrence of micronuclei in epithelial cells of the buccal mucosa. Cancer Epidemiol Biomarkers Prev 1995;4:751-758.
51.
Battaglia-Hsu SF, Akchiche N, Noel N, Alberto JM, Jeannesson E, Orozco-Barrios CE, et al: Vitamin B12 deficiency reduces proliferation and promotes differentiation of neuroblastoma cells and up-regulates PP2A, proNGF, and TACE. Proc Natl Acad Sci USA 2009;106:21930-21935.
52.
Walker PR, Smith B, Carson C, LeBlanc J, Sikorska M, Woodhouse CS, et al: Induction of apoptosis in neoplastic cells by depletion of vitamin B12. Cell Death Differ 1997;4:233-241.
53.
Thomas P, Harvey S, Gruner T, Fenech M: The buccal cytome and micronucleus frequency is substantially altered in Down's syndrome and normal ageing compared to young healthy controls. Mutat Res 2007;638:37-47.
54.
Cavuoto P, Fenech MF: A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev 2012;38:726-736.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.